7 Results for "

lipoprotein disorders

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "lipoprotein disorders" in MCE Product Catalog:

Cat. No.: HY-151123A
CAS No.: 2172851-58-8
Purity:  92.70%
Synonyms: AKCEA-APO(a)-LRx sodium; ISIS 681257 sodium; TQJ230 sodium
Research Areas:  

Metabolic Disease

Pelacarsen sodium (ISIS 681257 sodium) is a GalNAc3-conjugated 2′-MOE-modified antisense oligonucleotide. Pelacarsen sodium reduces apo (a) .
loading...
    loading...
Cat. No.: HY-151123
CAS No.: 1637637-70-7
Synonyms: AKCEA-APO(a)-LRx; ISIS 681257; TQJ230
Research Areas:  

Metabolic Disease

Pelacarsen (ISIS 681257) is a GalNAc3-conjugated 2′-MOE-modified antisense oligonucleotide. Pelacarsen reduces apo (a) .
loading...
    loading...
Cat. No.: HY-163436
CAS No.: 1338190-14-9
Research Areas:  

Metabolic Disease

F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .
loading...
    loading...
Cat. No.: HY-132187
CAS No.: 1670-26-4
Purity:  99.50%
Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a Kd of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes .
loading...
    loading...
Cat. No.: HY-113288
CAS No.: 474-60-2
Purity:  ≥99.0%
Target:  

LDLR

Research Areas:  

Metabolic Disease

Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .
loading...
    loading...
Cat. No.: HY-D3398
FlavAc is a fluorescent dye (with an excitation wavelength of 980 nm) for real-time in vivo imaging of lipid metabolism disorders, including early fatty liver disease and atherosclerotic plaques. FlavAc specifically integrates into endogenous lipoproteins, primarily low-density lipoprotein (LDL), and shows no brightness enhancement when bound to albumin. FlavAc forms aggregates in aqueous solutions, leading to fluorescence quenching; however, when integrated into lipoproteins, such aggregation decreases, forming stable fluorescent complexes with enhanced brightness. FlavAc can selectively illuminate LDL upon laser irradiation .
loading...
    loading...
Cat. No.: HY-182014
CAS No.: 2408041-54-1
Target:  

LXR

TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
loading...
    loading...